Worthington Steel Investor Presentation | June 2025 Safe Harbor Statement Selected statements contained in this release constitute "forward-looking statements," as that term is used in the Private Securities Litigation Reform Act of 1995 (the "Act"). The Company wishes to take advantage of the safe harbor provisions included in the Act. Forward-looking statements reflect the Company's current expectations, estimates or projections concerning future results or events. These statements are often identified by ...

Financial Performance & Targets - Steelcase's mid-term financial targets include average annual organic revenue growth of 4-6%[6] - The company targets an adjusted operating income margin of 6-7% in the mid-term[6] - Steelcase aims for a free cash flow of approximately 5% of revenue in the mid-term[6] - In FY25, Steelcase's revenue reached $32 billion[17] with an adjusted EBITDA of $262 million[17] - Steelcase's net debt to adjusted EBITDA ratio was -04x at the end of FY25[17] Market Position & Strategy - Steelcase is a leading global office furniture market manufacturer with a research-based approach to innovation[14, 15] - The company's strategy focuses on leading the transformation of the workplace, expanding reach within markets, and strengthening profitability[38] - Steelcase is targeting $50 million+ in operational cost reductions from FY23[4, 49] Regional Performance - In FY25, the Americas segment accounted for 78% of Steelcase's revenue[19] - The international segment accounted for 22% of Steelcase's FY25 revenue[19]

Financial results FQ3 2025 Safe harbor statement During the course of this meeting, we may make projections or other forward-looking statements regarding market demand and supply, market and pricing trends and drivers, the impact of technologies such as AI, the impact of our reorganization, cost reductions, our manufacturing projects and related investments, expected product volume production, our market position, expected product announcements, capabilities of our future products and technologies, future e ...

公司议程 - 年度股东大会于2025年6月25日召开[1] - 会议议程包括：宣布会议开始和程序事项、提案和投票、CEO黄仁勋的业务更新、初步投票结果和休会、问答环节[11] - 管理层提议选举13名董事，任期至2026年[14]，批准2025财年高管薪酬方案[13]，以及批准普华永道会计师事务所担任2026财年独立注册会计师事务所[13]，批准修订和重述公司注册证书，以删除所有超级多数条款[13] - 股东提议包括：取消召开股东特别会议的持股期限要求[19]，采纳新的董事选举辞职治理政策[25]，修改现有劳动力数据报告[31] 业务更新 - 英伟达正在从GPU芯片公司转型为AI基础设施公司[36] - 人工智能工厂是新的基础设施[66]，预示着一场新的工业革命[41, 67] - Blackwell架构是“一台思考机器”，将引领新一波AI代理和机器人浪潮[70] - 公司拥有统一的架构，覆盖从云AI、企业AI、个人AI到边缘AI[61] 财务业绩 - 2025财年收入为1305亿美元，同比增长114%[54] - 毛利率为75.0%，同比增长2.3个百分点[54] - 营业收入为815亿美元，同比增长147%[54] - 摊薄后每股收益为2.94美元，同比增长147%[54]

Business Overview - CareDx is focused on a $6B+ market opportunity in transplant care[20, 29] - The company's mission is to improve long-term outcomes by providing innovative solutions throughout the entire transplant patient journey[19] - Over 70% of organ transplant centers use one or more of CareDx's digital patient journey solutions[63] Financial Performance - Full year 2023 revenue reached $280.3M, exceeding the high end of updated guidance[77] - Testing Services revenue for 2023 was $209.7M with approximately 165,700 patient results[77] - Patient and Digital Solutions revenue grew by 29% year-over-year to $37.1M in 2023[77] - Product revenue increased by 15% year-over-year to $33.5M in 2023[77] - The company repurchased 2.9 million shares for $27.5 million in 2023[77] - CareDx ended 2023 with approximately $235.4M in cash and marketable securities and no debt[77] Future Outlook - 2024 revenue guidance is set at $260M to $274M[101] - Non-GAAP operating expenses are projected to be between $207M and $215M in 2024[101]

Financial Performance & Growth - CareDx reported Q1 2025 revenue of $84.7 million, an 18% increase year-over-year[18] - Testing volume in Q1 2025 reached approximately 47100, a 12% increase year-over-year[18] - The company's non-GAAP gross margin for Q1 2025 was 685%, a 150 basis points increase[18] - Adjusted EBITDA for Q1 2025 was positive $4.6 million, a $6.4 million increase year-over-year[18] - CareDx is targeting a 15% 3-year revenue Compound Annual Growth Rate (CAGR) and aims for $500 million in revenue by 2027[61] - The company is aiming for a gross margin target of >70% and an adjusted EBITDA target of 20% by 2027[61] Market Position & Strategy - CareDx estimates the transplant services market to be a $50 billion market[24] - The company has performed approximately 1 million rejection monitoring tests[24] - Accounts with 3 or more CareDx solutions have 2x higher average patient acquisition and 2x the testing services revenue[34] Innovation & Pipeline - CareDx is expanding into cell therapy monitoring with products like AlloCell and AlloHeme[48, 55] - The company is launching new diagnostics, including HistoMap Kidney, AlloSure SPK, and AlloSure Heart PEDS[41]

Incision-Free Ablative Intervention With Vision TULSA – A real-time imaging guided therapy platform for ablation of prostate tissue malignant or benign Corporate Presentation | May 2025 © 2025 Profound Medical Corp. NASDAQ: PROF, TSX: PRN 1 • FDA cleared in August 2019; first commercial site in January 2020, AI assistant cleared in May 2024 • Using patient cash pay business model installed >50 sites, >3,000 patients treated • New reimbursement codes established by AMA, placed by CMS in urology Level 7, effe ...

Financial Performance & Growth - The company's LTM (Last Twelve Months) revenue as of September 30, 2022, was approximately $5.5 billion[13] - The company's LTM Adjusted EBITDA reached $895 million[82] - The company's LTM Free Cash Flow reached $550 million[87] - The company's revenue increased from $1.988 billion in FY17 to $5.481 billion LTM[82] - The company's Adjusted EBITDA margin was 16.3% LTM[82] Market Position & Strategy - The company estimates a total addressable market of approximately $46 billion[53] - The company estimates the 2022 U.S Healthcare Staffing Market is approximately $40 billion[54] - The company's revenue from Technology and Workforce Solutions was 12% of total revenue in Q3 2022[61] - The company spent $378 million with small businesses and diverse-owned companies[44] Capital Allocation & Debt - The company's total debt was $850 million as of September 30, 2022[92] - The company has $534 million in total available liquidity as of September 30, 2022[92]

Financial Performance & Outlook - FY2022 revenue reached $143.4 million with a gross margin of 19.1% and net income of $7.9 million, or $0.67 per share[16] - Q3 FY2023 revenue was $43.0 million with a gross margin of 13.5% and net income of $0.9 million, or $0.07 per share[16] - The company anticipates Q4 revenue to be between $26 million and $28 million, with a gross margin goal for FY2023 of 16-18%[16] - Jerash is operating at approximately 14 million pieces annual capacity as of March 31, 2022[19] Strategic Positioning & Growth - Jerash is the largest contract manufacturer of premium apparel brands in Jordan, operating six facilities near Amman[7] - The company has a workforce of over 5,500 employees, with 25% being local Jordanian and 75% being contracted workers from other countries[17] - Jerash is strategically positioned to capture greater opportunities in the region as apparel production moves to Jordan[11] - The company is expanding its global customer base, including its first European-based high-end apparel brand[10, 19] - Jerash is diversifying its product offerings, with pants & shorts accounting for 41%, jackets for 35%, crew neck & other for 17%, and polo shirts for 7% of total pieces sold in FY2022 (excluding PPE)[31] ESG & Operational Strengths - Jerash is recognized for its ESG responsibility, including supporting women in the supply chain and providing stable employment to Syrian refugees[26, 29] - The company is committed to environmental sustainability, including using solar energy, LED lighting, and environmentally friendly inks[29] - Jerash benefits from Jordan's low-cost, high-quality manufacturing economy and duty-free US and EU export agreements[22, 48] - The company is reducing revenue seasonality by balancing production capacity utilization, with 53% of revenue generated in the first half and 47% in the second half of FY2022[33]

Forward-Looking Statements Statements contained in this presentation that are not historical facts are forward-looking statements, which involve risks and uncertainties that could cause actual results to differ materially from those expressed in the forward- looking statements. Such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Please refer to the Company's Securities and Exchange Commission filings for further information ...